Biologics Contract Manufacturing Market

Biologics Contract Manufacturing Market (Biopharma CDMO / Biopharma CMO / Biologics Manufacturing): Industry Trends, Global and Regional Forecasts, till 2035: by Type of Service(s) Offered (API, FDF), Type of Biologic Manufactured (Antibodies, Cell Therapies, Vaccines and Other Biologics), Type of Expression System Used (Mammalian, Microbial and Others), Scale of Operation (Preclinical / Clinical and Commercial), Company Size (Small, Mid-sized, and Large and Very Large), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America and MENA)

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    958

  • Pages
    799

  • View Count
    63412

Table Of Contents

1 PREFACE
1.1. Biopharmaceutical Contract Manufacturing Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
 
2 RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
 
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
 
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS 
3.1. Chapter Overview
3.2. Market Dynamics
 
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
 
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
 
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
 
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
 
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
 
4 EXECUTIVE SUMMARY
 
5 INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Biopharmaceuticals
5.3. Expression Systems for Biopharmaceuticals
5.3.1. Insect Expression Systems
5.3.2. Mammalian Expression Systems
5.3.3. Microbial Expression Systems
5.3.3.1. Bacterial Expression Systems
5.3.3.2. Fungal Expression Systems
5.3.3.3. Yeast Expression Systems
5.3.4. Plant Expression Systems
5.3.5. Mammalian versus Microbial Expression Systems 
 
5.4. Manufacturing Process of Biopharmaceuticals
5.4.1. Upstream Processing
5.4.2. Fermentation
5.4.3. Downstream Processing
 
5.5. Overview of Contract Manufacturing
5.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
5.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
5.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations
5.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
5.7. Key Considerations While Selecting a Contract Manufacturing Partner
5.8. Future Perspectives 
 
6 MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of Service Offered
6.2.5. Analysis by Type of Biologic Manufactured
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Type of Expression System Used
6.2.8. Analysis by Type of Bioreactor Used
6.2.9. Analysis by Mode of Operation of Bioreactor
 
7 REGIONAL CAPABILITY ANALYSIS
7.1.  Chapter Overview
7.2. Key Assumptions and Parameter 
7.3. Overview of Biopharmaceutical Contract Manufacturing Facilities
7.3.1. Analysis by Type of Service Offered
7.3.2. Analysis by Scale of Operation
7.4.  Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
7.5.  Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
7.6.  Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
7.7.  Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
 
8 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA
8.1. Chapter Overview
8.2. Biopharmaceutical Contract Manufacturing in the US: Regulatory Scenario
8.3. Leading Biopharmaceutical CMOs in North America
 
8.3.1. AGC Biologics
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.2.1. Process Development
8.3.1.2.2. cGMP Manufacturing
8.3.1.2.3. Quality and Regulatory Services
8.3.1.2.4. Process Validation
8.3.1.3. Financial Information
8.3.1.4. Manufacturing Facilities
8.3.1.5. Recent Developments and Future Outlook
8.3.2. Catalent
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio
8.3.2.2.1. Cell Line Development
8.3.2.2.2. Biomanufacturing
8.3.2.2.3. ADCs and Bioconjugates Manufacturing
8.3.2.2.4. Biosimilars Development and Manufacturing
8.3.2.2.5. Fill / Finish Solutions and Delivery Services
8.3.2.2.6. Analytical Services
8.3.2.3. Clinical Supply Services
8.3.2.4. Financial Information
8.3.2.5. Manufacturing Facilities
8.3.2.6. Recent Developments and Future Outlook
 
8.3.3. FUJIFILM Diosynth Biotechnologies
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.3.2.1. Strain Development
8.3.3.2.2. Process Development
8.3.3.2.3. cGMP Manufacturing
8.3.3.2.4. Analytical Solutions
8.3.3.3. Financial Information
8.3.3.4. Manufacturing Facilities
8.3.3.5. Recent Developments and Future Outlook
 
8.3.4. KBI Biopharma
8.3.4.1. Company Overview
8.3.4.2. Service Portfolio
8.3.4.2.1. Process Development
8.3.4.2.2. Analytical Development
8.3.4.2.3. GMP Manufacturing
8.3.4.2.4. Clinical Cell Therapy Support
8.3.4.3. Manufacturing Facilities
8.3.4.4. Recent Developments and Future Outlook
 
8.3.5. Charles River Laboratories
8.3.5.1 Company Overview
8.3.5.2. Service Portfolio
8.3.5.2.1. Cell Sourcing
8.3.5.2.2. Cell and Gene Therapy Solutions
8.3.5.2.3. Biologics Testing Solutions
8.3.5.2.4. Avian Vaccine Services
8.3.5.2.5. QC Microbial Solutions
8.3.5.2.6. Scientific and Regulatory Advisory Services
8.3.5.3. Financial Information
8.3.5.4. Manufacturing Facilities
8.3.5.5. Recent Developments and Future Outlook
 
8.4. Other Leading Biopharmaceutical CMOs in North America
8.4.1. Cytiva
8.4.1.1. Company Overview
8.4.2. Patheon
8.4.2.1. Company Overview
8.4.3 Piramal Pharma Solutions
8.4.3.1. Company Overview
 
9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE
9.1. Chapter Overview
9.2. Biopharmaceutical Contract Manufacturing in Europe: Regulatory Scenario
9.2.1. EMA’s cGMP Regulations 
 
9.3. Leading Biopharmaceutical CMOs in Europe
 
9.3.1. Boehringer Ingelheim (BioXcellence)
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.1.2.1. Process Development
9.3.1.2.1.1. Expression Systems
9.3.1.2.1.2. Upstream Technology
9.3.1.2.1.3. Downstream Technology
9.3.1.2.1.4. Other Process Development Services
9.3.1.2.2. Quality Assurance
9.3.1.2.3. Fill / Finish Services
9.3.1.3. Financial Information
9.3.1.4. Manufacturing Facilities
9.3.1.5. Recent Developments and Future Outlook
 
9.3.2. Lonza
9.3.2.1. Company Overview
9.3.2.2. Service Portfolio
9.3.2.3. Manufacturing Services
9.3.2.4. Financial Information
9.3.2.5. Manufacturing Facilities
9.3.2.6. Recent Developments and Future Outlook
 
9.3.3. Sandoz
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio
9.3.3.3. Financial Information
9.3.3.4. Manufacturing Facilities
9.3.3.5. Recent Developments and Future Outlook
 
9.3.4. Vetter Pharma
9.3.4.1. Company Overview
9.3.4.2. Service Portfolio
9.3.4.3. Manufacturing Facilities
9.3.4.4. Recent Developments and Future Outlook

9.3.5. Miltenyi Biotec
9.3.5.1. Company Overview
9.3.5.2. Service Portfolio
9.3.5.3. Manufacturing Facilities
9.3.5.4. Recent Developments and Future Outlook
9.4. Other Leading Biopharmaceutical CMOs in Europe
9.4.1 Novasep
9.4.1.1. Company Overview

9.4.2 Olon
9.4.2.1. Company Overview
9.4.3 Rentschler Biopharma
9.4.3.1. Company Overview
 
10 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA-PACIFIC AND REST OF THE WORLD
10.1. Chapter Overview
10.2. Biopharmaceutical Contract Manufacturing in China
10.2.1. Biopharmaceutical Contract Manufacturing in China: Regulatory Scenario
10.3. Leading Biopharmaceutical CMOs in China
10.3.1. WuXi Biologics
10.3.1.1. Company Overview
10.3.1.2. Service Portfolio
10.3.1.2.1. Discovery Services
10.3.1.2.2. Development Services
10.3.1.2.3. Testing Services
10.3.1.2.4. Clinical Manufacturing Services
10.3.1.3. Financial Information
10.3.1.4. Manufacturing Facilities
10.3.1.5. Recent Developments and Future Outlook
 
10.4. Biopharmaceutical Contract Manufacturing in India
10.4.1. Biopharmaceutical Contract Manufacturing in India: Regulatory Scenario
 
10.5. Leading Biopharmaceutical CMOs in India
10.5.1. Kemwell Biopharma
10.5.1.1. Company Overview
10.5.1.2. Service Portfolio
10.5.1.2.1. Development Services for Biopharmaceuticals
10.5.1.2.2. Manufacturing Services for Biopharmaceuticals
10.5.1.3. Manufacturing Facilities
10.5.1.4. Recent Developments and Future Outlook
10.6. Biopharmaceutical Contract Manufacturing in Japan
10.6.1. Biopharmaceutical Contract Manufacturing in Japan: Regulatory Scenario
10.7. Leading Biopharmaceutical CMOs in Japan
10.7.1. Minaris Regenerative Medicine
10.7.1.1. Company Overview
10.7.1.2. Service Portfolio
10.7.1.2.1. Manufacturing Development Services
10.7.1.2.2. GMP Manufacturing
10.7.1.3. Manufacturing Facilities
10.7.1.4. Recent Developments and Future Outlook
10.8. Biopharmaceutical Contract Manufacturing in South Korea
10.8.1. Biopharmaceutical Contract Manufacturing in South Korea: Regulatory Scenario
 
10.9. Leading Biopharmaceutical CMOs in South Korea
10.9.2. Samsung Biologics
10.9.2.1. Company Overview
10.9.2.2. Service Portfolio
10.9.2.2.1. Process Development
10.9.2.2.2. Analytical Services
10.9.2.2.3. cGMP Manufacturing Services
10.9.2.2.4. Aseptic Fill / Finish Services
10.9.2.2.5. Quality Services
10.9.2.3. Financial Information
10.9.2.4. Manufacturing Facilities
10.9.2.5. Recent Developments and Future Outlook
 
10.10. Biopharmaceutical Contract Manufacturing in Australia
10.10.1. Biopharmaceutical Contract Manufacturing in Australia: Regulatory Scenario
 
10.11. Leading Biopharmaceutical CMOs in Australia
10.11.1. Cell Therapies
10.11.1.1. Company Overview
10.11.1.2. Service Portfolio
10.11.1.3. Manufacturing Facilities
10.11.1.4. Recent Developments and Future Outlook
 
10.12. Other Leading Biopharmaceutical CMOs in Asia-Pacific and Rest of the World
10.12.1 AcuraBio (Formerly Known as Luina Bio)
10.12.1.1. Company Overview
10.12.2 Celltrion
10.12.2.1. Company Overview
10.12.3 Takara Bio
10.12.3.1. Company Overview
 
11 NICHE BIOPHARMACEUTICAL SECTORS
11.1. Chapter Overview
11.2. Bispecific Antibodies
11.2.1. Approved and Clinical Bispecific Antibody Therapeutics: Overall Market Landscape
11.2.2. Bispecific Antibodies: Pipeline Analysis
11.2.2.1. Analysis by Phase of Development
11.2.2.2. Analysis by Target Indication
11.2.3. Bispecific Antibody Therapeutics: Technology Platforms
11.2.4. Key Considerations for Manufacturing and Associated Challenges
11.2.5. Role of  CMOs in Offering Services for Bispecific Antibodies
11.2.5.1. CMOs Offering Services for Bispecific Antibodies

11.3. Antibody Drug Conjugates (ADCs)
11.3.1. Components of ADCs
11.3.1.1. Antibody
11.3.1.2. Cytotoxin
11.3.1.3. Linker
11.3.2. Antibody Drug Conjugates (ADCs): Pipeline Analysis
11.3.2.1. Analysis by Status of Development
11.3.2.2. Analysis by Target Disease Indication
11.3.2.3. Most Active Players: Analysis by Number of Therapies
11.3.3. Antibody Drug Conjugate Developers
11.3.4. Manufacturing Process

11.4. Cell Therapies
11.4.5. Technical Challenges Related to Antibody Drug Conjugates Manufacturing
11.4.6. Role of  CMOs in Offering Services for ADCs
11.4.6.1. CMOs Offering Services for ADCs
11.4.1. Cell Therapies: Overall Market Landscape
11.4.2. Overview of Cell Therapy Manufacturing
11.4.2.1. Cell Therapy Manufacturing Models
11.4.2.1.1. Centralized Manufacturing
11.4.2.1.2. Decentralized Manufacturing
11.4.3. Key Challenges for Manufacturing Cell Therapies
11.4.4. Key Factors Impacting Cell Therapy Manufacturing
11.4.4.1. Characterization
11.4.4.2. Cost of Goods
11.4.4.3. Automation of Cell Therapy Manufacturing
11.4.5 Cell Therapies: Pipeline Analysis
11.4.5.1 Analysis by Type of Cell Manufactured
11.4.6. Stem Cell Therapies: Analysis by Phase of Development
11.4.7. T-Cell Therapies: Analysis by Phase of Development
11.4.8. Role of  CMOs in Offering Services for Cell Therapies
11.4.8.1. CMOs Offering Services for Cell Therapies
 
11.5. Gene Therapies 
11.5.1. Gene Therapies: Pipeline Analysis
11.5.1.1. Analysis by Stage of Development
11.5.1.2. Analysis by Phase of Development
11.5.1.3. Analysis by Type of Vector Used
11.5.1.3.1. Clinical Pipeline
11.5.1.3.2. Preclinical Pipeline
11.5.1.4. Analysis by Therapeutic Area
11.5.1.4.1. Clinical and Commercial Pipeline
11.5.1.4.2. Preclinical Pipeline
11.5.2. Role of  CMOs in Offering Services for Gene Therapies
11.5.2.1 CMOs Offering Services for Gene Therapies
 
11.6. Viral Vectors 
11.6.1. Viral Vectors: Pipeline Analysis
11.6.1.1. Analysis by Location of Viral Vectors Manufacturing Facilities
11.6.1.2.  Analysis by Type of Viral Vector Manufactured
11.6.2. Role of  CMOs in Offering Services for Viral Vectors
11.6.2.1. CMOs Offering Services for Viral Vectors
 
11.7. Plasmid DNA
11.7.1. Plasmid DNA: Pipeline Analysis
11.7.1.1. Analysis by Location of Manufacturing Facilities
11.7.2. Role of  CMOs in Offering Services for Plasmid DNA
11.7.2.1. CMOs Offering Services for Plasmid DNA
 
12 CASE STUDY: OUTSOURCING OF BIOSIMILARS
12.1. Chapter Overview
12.2. Overview of Biosimilars
12.3. Development Stages of Biosimilars
12.4. Regulatory Requirements for Licensing of Biosimilars
12.5. Need for Outsourcing Manufacturing Operations
12.6. Impact of Biosimilars on the Global Contract Manufacturing Market
12.6.1. Biosimilars: Historical Trend of FDA Approvals
12.7. Biosimilars Contract Manufacturing Service Providers
12.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations
 
13 CASE STUDY: COMPARISON OF SMALL AND  LARGE MOLECULE DRUGS / THERAPIES
13.1. Chapter Overview
13.2. Small Molecule and Large Molecule Drugs / Therapies
13.2.1. Comparison of General Characteristics
13.2.2. Comparison of Key Specifications
13.2.3. Comparison of Manufacturing Process
13.2.4. Comparison of Key Manufacturing Challenges
 
14 CASE STUDY: IN-HOUSE MANUFACTURING
14.1. Chapter Overview
14.2. In-House Manufacturing
14.2.1. Benefits Associated with In-House Manufacturing
14.2.2. Risks Associated with In-House Manufacturing
14.3. Outsourcing Trends in the Biopharmaceutical Industry
14.3.1. Types of Outsourcing Partners
 
14.4. Manufacturing Approaches Used for Approved Biologics, 2016-2022
14.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing
 
15 MAKE VERSUS BUY DECISION MAKING FRAMEWORK
15.1. Chapter Overview
15.2. Key Assumptions and Parameters
 
15.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
15.3.1. Scenario 1
15.3.2. Scenario 2
15.3.3. Scenario 3
15.3.4. Scenario 4
15.4. Conclusion
 
16 BIG PHARMA INITIATIVES
16.1.  Chapter Overview
16.2.  Biopharmaceutical Related Initiatives by Big Pharmaceutical Players
16.2.1.  Analysis by Number of Initiatives
16.2.2.  Analysis by Year of Initiative
16.2.3. Analysis by Purpose of Initiative
16.2.4.  Analysis by Type of Initiative
16.2.4.1.  Analysis by Type of Partnership
16.2.4.2.  Analysis by Type of Expansion
16.2.5.  Analysis by Scale of Operation
16.2.6.  Analysis by Type of Biologic Manufactured
16.2.7. Analysis of Big Pharma Players by Year of Initiative
16.2.8. Analysis of Big Pharma Players by Purpose of Initiative
16.2.9.  Analysis by Year and Type of Initiative
16.2.10.  Analysis of Big Pharma Players by Region of Expansion
16.2.11. Analysis of Big Pharma Players by Type of Biologic Manufactured
 
17 PARTNERSHIPS AND COLLABORATIONS
17.1. Chapter Overview
17.2. Partnership Models
 
17.3. Biopharmaceutical Contract Manufacturing: Partnerships and Collaborations
17.3.1. Analysis by Year of Partnership
17.3.2. Analysis by Type of Partnership
17.3.3. Analysis by Year and Type of Partnership
17.3.4. Analysis by Type of Biologic Manufactured
 
17.3.5. Analysis by Year of Partnership and Type of Biologic Manufactured
17.3.6. Analysis by Type of Partnership and Type of Biologic Manufactured
17.3.7. Analysis by Scale of Operation
17.3.8. Analysis by Therapeutic Area
17.3.9. Most Active Players: Analysis by Number of Partnerships
17.3.10. Analysis by Geography
17.3.10.1. Local and International Agreements
17.3.10.2.  Intracontinental and Intercontinental Agreements
 
18 MERGERS AND ACQUISITIONS
18.1. Chapter Overview 
18.2. Merger and Acquisition Models
18.3. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
18.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
18.3.2. Analysis by Type of Acquisition
18.3.3. Analysis by Geography
18.3.3.1. Local and International Mergers and Acquisitions
18.3.3.2. Intracontinental and Intercontinental Mergers and Acquisitions
18.3.3.3. Year-wise Trend in North America, Europe and Asia-Pacific
18.3.4 Most Active Acquirers: Analysis by Number of Acquisitions
18.3.5 Analysis by Key Value Drivers
18.3.6. Analysis by Year of Acquisition and Key Value Drivers
18.3.7. Analysis by Type of Biologic Manufactured
18.3.8. Analysis by Key Value Drivers and Type of Biologic Manufactured
18.4. Key Acquisitions: Deal Multiples
18.4.1. Year-wise Trend of Deal Multiple Amount
 
19 RECENT EXPANSIONS
19.1. Chapter Overview
19.2. Biopharmaceutical Contract Manufacturing: Recent Expansions
19.2.1. Analysis by Year of Expansion
19.2.2. Analysis by Purpose of Expansion
19.2.3. Analysis by Year and Purpose of Expansion
19.2.4. Analysis by Type of Biologic Manufactured
19.2.5. Analysis by Purpose of Expansion and Type of Biologic Manufactured
19.2.6. Analysis by Location of Expanded Facility
19.2.7.  Most Active Players: Analysis by Number of Recent Expansions
19.2.8.  Analysis by Purpose of Expansion and Location of Expanded Facility
19.2.9. Analysis by Amount Invested
19.2.10.  Recent Expansions: 2016-2020 and 2021-2023 Scenario
 
20 RECENT DEVELOPMENTS
20.1. Chapter Overview
20.2. Types of Funding
20.3. Biopharmaceutical Contract Manufacturing: Funding and Investment Analysis
20.3.1. Analysis by Year of Funding
20.3.2. Analysis by Amount Invested
20.3.3. Analysis by Type of Funding
20.3.4. Analysis by Year and Type of Funding 
20.3.5. Analysis of Funding Instances and Amount Invested by Geography (Continent)
20.3.6. Analysis of Funding Instances and Amount Invested by Geography (Country)
20.3.7. Most Active Players: Analysis by Number of Funding Instances
20.3.8. Most Active Players: Analysis by Total Amount Raised 
20.3.9. Leading Investors: Analysis by Number of Funding Instances 
20.3.10. Leading Investors: Analysis by Total Amount Raised 
20.4. Technological Advancements
20.4.1. Single-Use Technology
20.4.2. Process Analytical Technology (PAT)
20.4.3. Continuous Processing
20.4.4. Quality by Design (QbD) in Bio-processing
20.4.5. Modular / Podular Biopharma Facilities
 
21 CAPACITY ANALYSIS
21.1.  Chapter Overview
21.2.  Key Assumptions and Methodology
21.3.  Biopharmaceutical Contract Manufacturing: Global Installed Capacity
21.3.1. Analysis by Company Size
21.3.2.  Analysis by Type of Expression System Used
21.3.3.  Analysis by Geography
21.3.3.1. Analysis of Biopharmaceutical Contract Manufacturing Capacity in North America
 
21.3.3.2. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Europe
21.3.3.3. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
21.3.3.4. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
21.4.  Concluding Remarks
 
22 DEMAND ANALYSIS
22.1.  Chapter Overview
22.2.  Key Assumptions and Methodology
22.3.  Global Demand for Biopharmaceuticals
22.4. Global Demand for Emerging Novel Biologics
22.4.1. Global Demand for ADC Therapeutics
22.4.2. Global Demand for Cell Therapy Manufacturing
 
23. TOTAL COST OF OWNERSHIP FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS 
23.1. Chapter Overview 
23.2. Key Parameters 
23.3. Assumptions and Methodology 
23.4. Total Cost of Ownership (Sample Dataset) 
23.5. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
23.5.1. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0 
23.5.2. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20 
 
23.7. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
23.7.1. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0 
23.7.2. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20 
 
24 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.1. Scenario Analysis
24.3.1.1. Conservative Scenario
24.3.1.2. Optimistic Scenario
 
24.4. Key Market Segmentations
 
25 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF SERVICE OFFERED
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
 
25.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, 2023 and 2035
25.3.1. API Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.2. FDF Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
25.4. Data Triangulation and Validation
 
26 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
 
26.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, 2023 and 2035
26.3.1. Antibodies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.2. Cell Therapies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.3. Vaccines: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.4. Other Biologics: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
26.4. Data Triangulation and Validation
 
27 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
 
27.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2023 and 2035
27.3.1. Mammalian Expression Systems: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.2. Microbial Expression Systems: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.3. Other Expression Systems: Historical Trends (2018-2022)  and Forecasted Estimates (2023-2035)
27.4. Data Triangulation and Validation
 
28 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
 
28.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and 2035
28.3.1. Preclinical / Clinical Operations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.2. Commercial Operations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
28.4. Data Triangulation and Validation
 
29 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
 
29.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
29.3.1. Small Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.3.2. Mid-sized Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.3.3. Large and Very Large Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
29.4. Data Triangulation and Validation
 
30 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
 
30.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035
30.3.1. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.1.1. US: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.1.2. Canada: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
30.3.2. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.1. Italy: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.2. Germany: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.3. France: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.4. Spain: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.5. UK: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.6. Rest of Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
30.3.3. Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.1. China: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.2. India: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.3. South Korea: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.4. Japan: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.5. Rest of Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
30.3.4. Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.5. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.8. Data Triangulation and Validation
 
31 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY LEADING PLAYERS
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players
31.4. Data Triangulation and Validation
 
32 CASE STUDY: VIRTUAL PHARMACEUTICAL COMPANIES
32.1. Chapter Overview
32.2. Historical Evolution of the Virtual Business Model
32.3. Virtual Pharmaceutical Companies as a Subset of the Overall Biopharmaceutical Industry
32.4. Advantages Associated with Outsourcing Operations to Virtual Service Providers
32.5. Key Challenges Associated with Outsourcing Operations to Virtual Service Providers
 
33. SWOT ANALYSIS 
33.1 Chapter Overview
33.2. Strengths
33.3. Weaknesses
33.4. Opportunities
33.5. Threats
33.6. Comparison of SWOT Factors
33.7. Conclusion
 
34 FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET
34.1. Chapter Overview
34.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
34.3. Shift from One-time Contracts to Strategic Partnerships
34.4. Integration / Adoption of  New and Innovative Technologies
34.4.1.  Single-use Bioreactors
34.4.2.  Novel Bioprocess Techniques
34.4.3.  Bioprocess Automation
 
34.5. Focus on Niche Therapeutic Areas
34.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
34.7. Capability Expansion by CMOs to become One-Stop-Shops
34.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
34.9. Increase in Financial Inflow and Outsourcing Budgets
34.10. Challenges Faced by Sponsors and Service Providers
34.10.1. Concerns Related to Single-use Systems
34.10.2. Issues Related to Capacity Fluctuations
34.11. Concluding Remarks
 
35 CONCLUSION
 
36 EXECUTIVE INSIGHTS
36.1. Chapter Overview
36.2. RoslinCT
36.2.1. Company Snapshot
36.2.2. Interview Transcript
 
36.3. Chapter Overview
36.3. JAFRAL Biosolutions
36.3.1. Company Snapshot
36.3.2. Interview Transcript
 
36.4. Chapter Overview
36.4. Discovery Life Sciences
36.4.1. Company Snapshot
36.4.2. Interview Transcript
 
36.5. Chapter Overview
36.5. Bioworkshops
36.5.1. Company Snapshot
36.5.2. Interview Transcript

36.6. Aldevron
36.6.1. Company Snapshot
36.6.2. Interview Transcript
 
36.7. Resilience
36.7.1. Company Snapshot
36.7.2. Interview Transcript
 
36.8. Minaris Regenerative Medicine
36.8.1. Company Snapshot
36.8.2. Interview Transcript
 
36.9. 53Biologics
36.9.1. Company Snapshot
36.9.2. Interview Transcript
 
36.10. Richter-Helm BioLogics
36.10.1. Company Snapshot
36.10.2. Interview Transcript
 
37 APPENDIX I: TABULATED DATA
 
38 APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
 
39 APPENDIX III: DETAILS OF PARTNERSHIPS AND COLLABORATIONS

List Of Figures

Figure 2.1 Research Methodology: Project Methodology      
Figure 2.2 Research Methodology: Forecast Methodology      
Figure 2.3  Research Methodology: Robust Quality Control      
Figure 2.4  Research Methodology: Key Market Segmentation      
Figure 3.1  Lessons Learnt from Past Recessions      
Figure 4.1  Executive Summary: Overall Market Landscape      
Figure 4.2  Executive Summary: Regional Capability Analysis      
Figure 4.3  Executive Summary: Partnerships and Collaborations      
Figure 4.4  Executive Summary: Mergers and Acquisitions      
Figure 4.5  Executive Summary: Recent Expansions      
Figure 4.6  Executive Summary: Funding and Investment Analysis      
Figure 4.7  Executive Summary: Demand Analysis      
Figure 4.8  Executive Summary: Total Cost of Ownership      
Figure 4.9  Executive Summary: Market Forecast and Opportunity Analysis      
Figure 5.1  Types of Biopharmaceuticals      
Figure 5.2  Types of Expression Systems Used for the Production of Biopharmaceuticals      
Figure 5.3  Stages of the Biomanufacturing Process      
Figure 5.4  Types of Third-Party Service Providers      
Figure 5.5  Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations      
Figure 6.1  Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment      
Figure 6.2  Biopharmaceutical Contract Manufacturers: Distribution by Company Size      
Figure 6.3  Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)      
Figure 6.4  Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)      
Figure 6.5  Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region) Figure 6.6  Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered     
Figure 6.7  Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured      
Figure 6.8  Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters (Region)      
Figure 6.9  Biopharmaceutical Contract Manufacturers: Distribution by Type of  Biologic Manufactured and Company Size      
Figure 6.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation       
Figure 6.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation       
Figure 6.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used       
Figure 6.13 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used and Location of Headquarters (Region)       
Figure 6.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used       
Figure 6.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of  Bioreactor      
Figure 7.1   Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities       
Figure 7.2  Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered       
Figure 7.3  Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation       
Figure 7.4  Regional Capability Analysis: Biopharmaceutical Contract  Manufacturing Facilities in North America      
Figure 7.5  Regional Capability Analysis: Biopharmaceutical Contract  Manufacturing Facilities in Europe     
Figure 7.6  Regional Capability Analysis: Biopharmaceutical Contract  Manufacturing Facilities in Asia-Pacific      
Figure 7.7  Regional Capability Analysis: Biopharmaceutical Contract  Manufacturing Facilities in Rest of the World     
Figure 8.1  Biopharmaceutical Contract Manufacturing Industry: The US Market Scenario      
Figure 8.2  Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges      
Figure 8.3  US FDA Guidelines: Elements of a Quality Agreement      
Figure 8.4  US FDA Guidelines: Key Considerations for Biologic Manufacturing Operations      
Figure 8.5  AGC Biologics: Annual Revenues, FY 2018-H1 FY 2023 (JPY Billion)      
Figure 8.6  Catalent: Service Portfolio       
Figure 8.7  Catalent: Biosimilars Service Portfolio      
Figure 8.8  Catalent: Annual Revenues, FY 2018-FY 2023 (USD Billion)      
Figure 8.9   FUJIFILM Diosynth Biotechnologies: Service  Portfolio      
Figure 8.10 FUJIFILM  Diosynth Biotechnologies: Annual  Revenues, FY 2018-FY 2022 (JPY Billion)     
Figure 8.11 FUJIFILM Holdings: Annual Revenues by Business  Divisions, FY 2022 (JPY Billion)      
Figure 8.12 KBI Biopharma: Service Portfolio       
Figure 8.13 Charles River Laboratories: Service Portfolio       
Figure 8.14 Charles River Laboratories: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)       
Figure 9.1  Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges      
Figure 9.2  EMA GMP Guidelines: Key Considerations for the Contract Giver, Contract Acceptor and the Contract      
Figure 9.3  Boehringer Ingelheim  (BioXcellenece): Service Portfolio     
Figure 9.4  Boehringer Ingelheim: Annual Revenues, FY 2018-H1 FY  2023 (EUR Billion)     
Figure 9.5  Lonza: Service Portfolio      
Figure 9.6  Lonza: Annual Revenues, FY 2018-H1 FY 2023 (CHF Billion)      
Figure 9.7  Lonza: Annual Revenues by Business Divisions (CHF Billion)      
Figure 9.8 Sandoz: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)       
Figure 9.9 Vetter Pharma: Service  Portfolio      
Figure 10.1 Chinese Regulatory Guidelines: Key Considerations for the Contract Giver       
Figure 10.2 Chinese Regulatory Guidelines: Key Considerations for the Contract Acceptor       
Figure 10.3 Chinese Regulatory Guidelines: Key Aspects of the Contract       
Figure 10.5 WuXi Biologics: Service Portfolio       
Figure 10.6 Wuxi Biologics: Annual Revenues, FY 2018-H1 FY 2023 (RMB Billion)       
Figure 10.7 Biopharmaceutical Contract Manufacturing in India: Growth Drivers       
Figure 10.8 Kemwell Biopharma: Service Portfolio       
Figure 10.9 Minaris Regenerative Medicine: Service Portfolio       
Figure 10.10 Samsung Biologics: Service   Portfolio       
Figure 10.11 Samsung Biologics: Annual  Revenues, FY 2018-H1 FY 2023 (KRW Billion)       
Figure 10.12 Cell Therapies: Service   Portfolio       
Figure 11.1 Basic Structure of an Antibody       
Figure 11.2 Approved and Clinical  Bispecific Antibody Therapeutics: Distribution by Phase of Development      
Figure 11.3 Approved and Clinical  Bispecific Antibody Therapeutics:  Distribution by Target  Indication    
Figure 11.4 Structure of an Antibody Drug Conjugate (ADC)       
Figure 11.5 Antibody Drug Conjugates: Distribution by Status of Development       
Figure 11.6 Antibody Drug Conjugates: Distribution by Target Disease Indication      
Figure 11.7 Most Active Players: Distribution by Number of Therapies       
Figure 11.8 Decentralized Manufacturing: Process Model       
Figure 11.11 Cell Therapies: Challenges and Drivers       
Figure 11.10 Cell Therapies: Potency as Critical Quality Attribute       
Figure 11.11 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured       
Figure 11.12 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured       
Figure 11.13 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured       
Figure 11.14 Stem Cell Therapies:  Distribution by Phase of Development      
Figure 11.15 T-Cell Therapies: Distribution by Phase of Development       
Figure 11.16 Gene Therapies: Distribution by Stage of Development       
Figure 11.17 Gene Therapies: Distribution by Phase of Development       
Figure 11.18 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used       
Figure 11.19 Early-stage Pipeline of Gene  Therapies: Distribution by  Type of Vector Used      
Figure 11.20 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area       
Figure 11.21 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area       
Figure 11.22 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise)       
Figure 11.23 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured       
Figure 11.24 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility       
Figure 12.1 Manufacturing Stages of a Biosimilar Product       
Figure 12.2 Analytical and Functional Characterization Methods for Key Biosimilar Product       
Figure 12.3 Regulatory Process Adopted for Licensing of a Biosimilar  Product      
Figure 12.4 Need for Outsourcing  Biosimilar Manufacturing Operations      
Figure 12.5 Biosimilars: Historical Trend of  FDA Approvals, 2015-2022       
Figure 12.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations       
Figure 13.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022       
Figure 13.2 Small Molecules versus Large Molecules: Comparison of  Manufacturing Process      
Figure 14.1 Benefits Associated with In-House Manufacturing       
Figure 14.2 Risks Associated with In-House Manufacturing       
Figure 14.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships       
Figure 15.1 Make versus Buy Decision Making Framework       
Figure 15.2 Make versus Buy Decision Making Framework: Possible Scenarios       
Figure 16.1 Big Pharma Initiatives: Distribution of Players by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives      
Figure 16.2 Big Pharma Initiatives: Cumulative Year-wise Trend, Pre-2005-2023      
Figure 16.3 Big Pharma Initiatives: Distribution by Purpose of Initiative      
Figure 16.4 Big Pharma Initiatives: Distribution by Type of Initiative      
Figure 16.5 Big Pharma Initiatives: Distribution by Type of Partnership      
Figure 16.6 Big Pharma Initiatives: Distribution by Type of Expansion      
Figure 16.7 Big Pharma Initiatives: Distribution by Scale of Operation      
Figure 16.8 Big Pharma Initiatives: Distribution by Type of Biologic Manufactured      
Figure 16.9 Big Pharma Initiatives: Distribution of Players by Year and Number of Initiatives      
Figure 16.10 Big Pharma Initiatives: Distribution of Players by Purpose of Initiative       
Figure 16.11Big Pharma Initiatives: Distribution by Year  and Type of Initiative       
Figure 16.12Big Pharma Initiatives: Distribution of Players by Region of  Expansion        
Figure 16.13Big Pharma Initiatives: Distribution of Players by Type  of Biologic Manufactured       
Figure 17.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023       
Figure 17.2 Partnerships and Collaborations: Distribution by Type of Partnership       
Figure 17.3 Partnerships and  Collaborations: Distribution by Year and Type of Partnership     
Figure 17.4 Partnerships and  Collaborations: Distribution by Type of Biologic Manufactured     
Figure 17.5 Partnerships and  Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured    
Figure 17.6 Partnerships and  Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured    
Figure 17.7 Partnerships and  Collaborations: Distribution by Scale of Operation     
Figure 17.8 Partnerships and  Collaborations: Distribution by Therapeutic Area     
Figure 17.9 Most Active Players: Distribution by Number of  Partnerships     
Figure 17.10 Partnerships and Collaborations: Local and  International Agreements     
Figure 17.11 Partnerships and Collaborations: Intracontinental  and Intercontinental Agreements    
Figure 18.1 Mergers and Acquisitions: Year-Wise Cumulative Trend,  2015- 2023     
Figure 18.2 Mergers and Acquisitions:  Distribution by Type of  Acquisition     
Figure 18.3 Local and International  Mergers and Acquisitions      
Figure 18.4 Intracontinental and  Intercontinental Mergers and  Acquisitions     
Figure 18.5 Mergers and  Acquisitions: Year-Wise Trend  in North America, Europe and  Asia-Pacific (2015-2023)    
Figure 18.6 Most Active  Acquirers: Distribution by  Number of Acquisitions     
Figure 18.7 Catalent Biologics:  Information on Key  Acquisitions     
Figure 18.8 Mergers and  Acquisitions: Distribution by  Key Value Drivers     
Figure 18.9 Mergers and  Acquisitions: Distribution by  Year of Acquisition and Key  Value Drivers    
Figure 18.10 Mergers and  Acquisitions: Distribution by  Type of Biologic Manufactured     
Figure 18.11 Mergers and  Acquisitions: Distribution by  Key Value Drivers and Type of  Biologic Manufactured    
Figure 18.12 Mergers and  Acquisitions: Year-Wise Trend  of Deal Multiple Amount  (USD Million)    
Figure 19.1 Recent Expansions: Cumulative Year-wise Trend, 2016-2023       
Figure 19.2 Recent Expansions: Distribution by Purpose of Expansion       
Figure 19.3 Recent Expansions: Distribution by Year and  Purpose of Expansion     
Figure 19.4 Recent Expansions: Distribution by Type of  Biologic Manufactured     
Figure 19.5 Recent Expansions: Distribution by Purpose of  Expansion and Type of  Biologic Manufactured    
Figure 19.6 Recent Expansions: Distribution by Location of  Expanded Facility     
Figure 19.7 Most Active Players: Distribution by Number of  Recent Expansions     
Figure 19.8 Recent Expansions: Distribution by Purpose of  Expansion and Location of  Expanded Facility    
Figure 19.9 Recent Expansions: Distribution by Amount  Invested (USD Million)      
Figure 19.10 Recent Expansions: Regional  Comparison 2016-2020 and  2021-2023 Scenario     
Figure 20.1 Funding and Investment  Analysis: Cumulative Year- wise Trend, 2016-2023     
Figure 20.2 Funding and Investment  Analysis: Cumulative Year- wise Trend  by Amount  Invested, 2016-2023 (USD  Million)  
Figure 20.3 Funding and Investment  Analysis: Distribution of  Funding Instances by Type of  Funding    
Figure 20.4 Funding and Investment  Analysis: Distribution of  Amount Invested by Type of  Funding (USD Million)     
Figure 20.5 Funding and Investment  Analysis: Distribution by Year  and Type of Funding     
Figure 20.6 Funding and Investment  Analysis: Distribution of  Funding Instances and Total  Amount Invested by  Geography (Continent) (USD  Million)  
Figure 20.7 Funding and Investment  Analysis: Distribution of  Funding Instances and Total  Amount Invested by  Geography (Country) (USD  Million)  
Figure 20.8 Most Active Players: Distribution by Number of  Funding Instances     
Figure 20.9 Most Active Players: Distribution by Total Amount  Raised (USD Million)     
Figure 20.10 Leading Investors: Distribution by Number of  Funding Instances     
Figure 20.11 Leading Investors: Distribution by Amount  Invested (USD Million)     
Figure 21.1 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Company Size    
Figure 21.2 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Type of Expression System Used    
Figure 21.3 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Location of Manufacturing Facilities   
Figure 21.4 Biopharmaceutical Contract Manufacturing Capacity in  North America     
Figure 21.5 Biopharmaceutical Contract Manufacturing Capacity in  Europe     
Figure 21.6 Biopharmaceutical Contract Manufacturing Capacity in  Asia-Pacific     
Figure 21.8 Biopharmaceutical Contract Manufacturing Capacity in  Rest of the World    
Figure 22.1 Global Demand for Biopharmaceuticals, 2023-2035 (in kilograms)     
Figure 22.2 Global Demand for ADC Therapeutics, 2023-2035  (in kilograms)     
Figure 22.3 Global Demand for Cell Therapies, 2023-2035 (in terms of Number of Patients)     
Figure 22.4 Global Demand for Cell Therapies, 2023-2035 (Billion Cells)     
Figure 23.1 Total Cost of Ownership: Capital Expenditures (CAPEX)      
Figure 23.2 Total Cost of Ownership: Operational Expenditures  (OPEX)     
Figure 23.3 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20  (USD Million)   
Figure 23.4 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0:  Distribution by CAPEX (USD  Million)  
Figure 23.5 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20:  Distribution by OPEX (USD  Million)  
Figure 23.6 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract  Manufacturing Organizations, Y0-Y20 (USD Million)   
Figure 23.7 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract  Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)  
Figure 23.8 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract  Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)  
Figure 24.1 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (2018-2022)    
Figure 24.2 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (2023-2035), Base Scenario (USD Billion)   
Figure 24.3 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Billion)   
Figure 24.4 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Billion)   
Figure 25.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Type of  Service Offered, 2018, 2023  and 2035   
Figure 25.2 Biopharmaceutical Contract  Manufacturing Market for API Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion) 
Figure 25.3 Biopharmaceutical Contract  Manufacturing Market for FDF Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion) 
Figure 26.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Type of  Biologic Manufactured, 2018,  2023 and 2035   
Figure 26.2 Biopharmaceutical Contract  Manufacturing Market for Antibodies, Historical Trends (2018-2022) and Forecasted Estimates (USD Billion)
Figure 26.3 Biopharmaceutical Contract  Manufacturing Market for Cell Therapies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD  Billion)  
Figure 26.4 Biopharmaceutical Contract  Manufacturing Market for Vaccines, Historical Trends  (2018-2022) and Forecasted Estimates (2023-2035) (USD  Billion)  
Figure 27.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Type of  Expression System Used, 2018,  2023 and 2035   
Figure 27.2 Biopharmaceutical Contract  Manufacturing Market for Mammalian Expression Systems, Historical Trends  (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion) 
Figure 27.3 Biopharmaceutical Contract  Manufacturing Market for Microbial Expression Systems, Historical Trends  (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion) 
Figure 27.4 Biopharmaceutical Contract  Manufacturing Market for Other Expression  Systems, Historical Trends  (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion) 
Figure 28.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and  2035   
Figure 28.2 Biopharmaceutical Contract  Manufacturing Market for Preclinical / Clinical Operations, Historical Trends  (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Figure 28.3 Biopharmaceutical Contract  Manufacturing Market for Commercial Operations, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (USD  Billion) 
Figure 29.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035    
Figure 29.2 Biopharmaceutical Contract  Manufacturing Market for Small Companies, Historical  Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion) 
Figure 29.3 Biopharmaceutical Contract  Manufacturing Market for Mid- sized Companies, Historical Trends (2018-2022) and Forecasted  Estimates (2023- 2035) (USD Billion) 
Figure 29.4 Biopharmaceutical Contract  Manufacturing Market for Large and Very Large Companies, Historical Trends (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion) 
Figure 30.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035    
Figure 30.2 Biopharmaceutical Contract  Manufacturing Market in North America, Historical Trends  (2018-2022) and Forecasted Estimates (2023-2035) (USD  Billion)  
Figure 30.3 Biopharmaceutical Contract  Manufacturing Market in the US, Historical Trends (2018- 2022) and Forecasted Estimates  (2023-2035) (USD Billion)   
Figure 30.4 Biopharmaceutical Contract  Manufacturing Market in Canada, Historical Trends (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.5 Biopharmaceutical Contract  Manufacturing Market in  Europe, Historical Trends (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.6 Biopharmaceutical Contract  Manufacturing Market in Italy,  Historical Trends (2018-2022)  and Forecasted Estimates  (2023-2035) (USD Billion)   
Figure 30.7 Biopharmaceutical Contract  Manufacturing Market in Germany, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.8 Biopharmaceutical Contract  Manufacturing Market in France, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.9 Biopharmaceutical Contract  Manufacturing Market in Spain, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.10 Biopharmaceutical Contract  Manufacturing Market in the UK, Historical Trends  (2018- 2022) and Forecasted Estimates  (2023-2035) (USD Billion)  
Figure 30.11 Biopharmaceutical Contract  Manufacturing Market in Rest of Europe, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.12 Biopharmaceutical Contract  Manufacturing Market in Asia- Pacific, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.13 Biopharmaceutical Contract  Manufacturing Market in  China, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.14 Biopharmaceutical Contract  Manufacturing Market in India, Historical Trends (2018-2022)  and Forecasted Estimates  (2023-2035) (USD Billion)   
Figure 30.15 Biopharmaceutical Contract  Manufacturing Market in South  Korea, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.16 Biopharmaceutical Contract  Manufacturing Market in Japan, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)   
Figure 30.17 Biopharmaceutical Contract  Manufacturing Market in Rest of Asia-Pacific, Historical  Trends (2018-2022) and  Forecasted  Estimates (2023- 2035) (USD Billion) 
Figure 30.18 Biopharmaceutical Contract  Manufacturing Market in Latin  America, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.19 Biopharmaceutical Contract  Manufacturing Market in Middle East and North Africa,  Historical Trends (2018-2022)  and Forecasted Estimates  (2023-2035) (USD Billion)  
Figure 30.20 Biopharmaceutical Contract  Manufacturing Market:Distribution by Leading  Players (USD Billion)    
Figure 31.1 Overall Share of Virtual  Biopharmaceutical Companies in the Biopharmaceutical  Market (USD Billion)    
Figure 31.2 Overall Share of Virtual  Biopharmaceutical Companies in the Biopharmaceutical  Contract Manufacturing Market  in 2023 (USD Billion)   
Figure 32.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis     
Figure 32.2 Global Biopharmaceuticals  Market: Distribution of Number of FDA Approvals by  Year, 2005-2022    
Figure 32.3 Comparison of SWOT Factors:  Harvey Ball Analysis      
Figure 35.1 Concluding Remarks: Overall  Market Landscape      
Figure 35.2 Concluding Remarks: Partnerships and Collaborations     
Figure 35.3 Concluding Remarks: Mergers and Acquisitions      
Figure 35.4 Concluding Remarks: Funding and Investments      
Figure 35.5 Concluding Remarks: Recent Expansions      
Figure 35.6 Concluding Remarks: Capacity Analysis      
Figure 35.7 Concluding Remarks: Demand Analysis      
Figure 35.8 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)     
Figure 35.9 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)     

List Of Tables

Table 5.1 Mammalian versus Microbial Expression Systems
Table 6.1 List of Biopharmaceutical Contract Manufacturers
Table 6.2 Biopharmaceutical Contract Manufacturers: Information on Type of Service Offered
Table 6.3 Biopharmaceutical Contract Manufacturers: Information on Type of Biologic Manufactured
Table 6.6 Biopharmaceutical Contract Manufacturers: Information on Scale of Operation
Table 6.5 Biopharmaceutical Contract Manufacturers: Information on Type of Expression System Used
Table 6.6 Biopharmaceutical Contract Manufacturers: Information on Type of Bioreactor Used
Table 6.7 Biopharmaceutical Contract Manufacturers: Information on Mode of Operation of Bioreactor
Table 7.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
Table 7.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
Table 7.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific 
Table 7.4 List of Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Table 8.1 AGC Biologics: Company Overview
Table 8.2 AGC Biologics: Biologics Manufacturing Facilities
Table 8.3 AGC Biologics: Recent Developments and Future Outlook
Table 8.4 Catalent: Company Overview
Table 8.5 Catalent: Biologics Manufacturing Facilities
Table 8.6 Catalent: Recent Developments and Future Outlook
Table 8.7 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 8.8 FUJIFILM Diosynth Biotechnologies: Biologics Manufacturing Facilities
Table 8.9 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 8.10 KBI Biopharma: Company Overview
Table 8.11 KBI Biopharma: Biologics Manufacturing Facilities
Table 8.12 KBI Biopharma: Recent Developments and Future Outlook
Table 8.13 Charles River Laboratories: Company Overview
Table 8.14 Charles River Laboratories: Biologics Manufacturing Facilities
Table 8.15 Charles River Laboratories: Recent Developments and Future Outlook
Table 8.16  Cytiva: Company Overview
Table 8.17  Patheon: Company Overview
Table 8.18  Piramal Pharma Solutions: Company Overview
Table 9.1 FDA Quality Agreements and EMA cGMP Regulations: A Comparative Analysis 
Table 9.2 Boehringer Ingelheim: Company Overview
Table 9.3 Boehringer Ingelheim: Biologics Manufacturing Facilities
Table 9.4 Boehringer Ingelheim: Recent Developments and Future Outlook
Table 9.5 Lonza: Company Overview
Table 9.6 Lonza: Biologics Manufacturing Facilities
Table 9.7 Lonza: Recent Developments and Future Outlook
Table 9.8 Sandoz: Company Overview
Table 9.9 Sandoz: Biologics Manufacturing Facilities
Table 9.10 Sandoz: Recent Developments and Future Outlook
Table 9.11 Vetter Pharma: Company Overview
Table 9.12 Vetter Pharma: Biologics Manufacturing Facilities
Table 9.13 Vetter Pharma: Recent Developments and Future Outlook
Table 9.14 Miltenyi Biotec: Company Overview
Table 9.15 Miltenyi Biotec: Biologics Manufacturing Facilities
Table 9.16 Miltenyi Biotec: Recent Developments and Future Outlook
Table 9.17  Novasep: Company Overview
Table 9.18  Olon: Company Overview
Table 9.19  Rentschler Biopharma: Company Overview
Table 10.1 WuXi Biologics: Company Overview
Table 10.2 Wuxi Biologics: Biologics Manufacturing Facilities
Table 10.3 WuXi Biologics: Recent Developments and Future Outlook
Table 10.4 Kemwell Biopharma: Company Overview
Table 10.5 Kemwell Biopharma: Recent Developments and Future Outlook
Table 10.6 Minaris Regenerative Medicine: Company Overview
Table 10.7 Minaris Regenerative Medicine: Biologics Manufacturing Facilities
Table 10.8 Minaris Regenerative Medicine: Recent Developments and Future Outlook
Table 10.9 Samsung BioLogics: Company Overview
Table 10.10 Samsung BioLogics: Biologics Manufacturing Facilities
Table 10.11 Samsung BioLogics: Recent Developments and Future Outlook
Table 10.12 Cell Therapies: Company Overview
Table 10.13 Cell Therapies: Recent Developments and Future Outlook
Table 10.14 AcuraBio: Company Overview
Table 10.15 Celltrion: Company Overview
Table 10.16 Takara Bio: Company Overview 
Table 11.1 Bispecific Antibody Therapeutics: Information on Drug Candidate, Developer, Phase of Development and Target Antigen
Table 11.2 Bispecific Antibody Therapeutics: Information on Clinical Drug Candidates, Target Indications, Therapeutic Areas and Disease Segment
Table 11.3 Bispecific Antibody Therapeutics: List of Technology Platforms
Table 11.4 Bispecific Antibody Contract Manufacturers: List of Companies
Table 11.5 Commonly Used Cytotoxins for ADC Therapeutics
Table 11.6 Occupational Exposure Limit Bands, Safebridge Consultants
Table 11.7 Antibody Drug Conjugates: Information on Drug Candidates, Developers, Status of Development, Target Disease Indications and Therapeutic Areas
Table 11.8 Antibody Drug Conjugate Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 11.9 ADC Contract Manufacturers: List of Companies
Table 11.10 Cell-based Therapies: Applications 
Table 11.11 Cell-based Therapies: Commercialized Products, 
Table 11.12 Key Cell Therapy Manufacturing Steps
Table 11.13 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 11.14 Cell Therapy Manufacturing (Industry Players): Information on Type of Cell Manufactured
Table 11.15 Cell Therapy Contract Manufacturers: List of Companies
Table 11.16 Gene Therapy Contract Manufacturers: List of Companies
Table 11.17 Vector and Gene Therapy Manufacturers (Non-Industry players): Information on Type of Vector Manufactured
Table 11.18 Viral Vectors Contract Manufacturers: List of Companies 
Table 11.19 Plasmid DNA Manufacturing Service Providers: Information on Location of Manufacturing Facility
Table 11.20 Plasmid DNA Contract Manufacturers: List of Companies
Table 12.1 List of Biosimilars Contract Manufacturing Service Providers 
Table 13.1 Small Molecules and Large Molecules: Strengths and Weaknesses
Table 13.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
Table 13.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 14.1 List of FDA Approved Biologics (2016-2022)
Table 16.1 Big Pharma Initiatives: List of Biopharmaceutical Manufacturing Initiatives 
Table 17.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations, 2019-2023
Table 17.2 Partnerships and Collaborations: Information on Type of Biologic Manufactured
Table 18.1 Biopharmaceutical Contract Manufacturing: List of Mergers and Acquisitions, 2015-2023
Table 18.2 Mergers and Acquisitions: Information on Key Value Drivers and Type of Biologic Manufactured
Table 18.3 Mergers and Acquisitions: Information on Deal Multiples, 2015-2023
Table 19.1 Biopharmaceutical Contract Manufacturing: List of Recent Expansions, 2016-2023
Table 20.1 Biopharmaceutical Contract Manufacturing: List of Funding and Investments, 2016-2023
Table 20.2 Funding and Investment Analysis: Summary of Investments
Table 20.3 Funding and Investment Analysis: Summary of Venture Capital Funding
Table 21.1 Biopharmaceutical Contract Manufacturers: Information on Capacity (Sample Data Set)
Table 21.2 Capacity Analysis: Average Capacity per Category (Sample Data Set)
Table 21.3 Capacity Analysis: Average Capacity for Mammalian Expression Systems (Sample Data Set)
Table 21.4 Capacity Analysis: Average Capacity for Microbial Expression Systems (Sample Data Set)
Table 21.5  Capacity Analysis: Average Capacity for Other Expression Systems (Sample Data Set)
Table 21.6 Capacity Analysis: Global Production Capacity
Table 22.1 Annual Biomanufacturing Capacity, 2023-2035 (Million Liters)
Table 23.1 Total Cost of Ownership: Sample Dataset for Mid-sized Companies
Table 23.2 Total Cost of Ownership: Sample Dataset for Large / Very Large Companies
Table 31.1 List of Leading Biopharmaceutical Contract Manufacturing Companies
Table 32.1 List of Virtual Biopharmaceutical Companies
Table 36.1  RoslinCT: Key Highlights
Table 36.2  Jafral Biosolutions: Key Highlights
Table 36.3  Discovery Life Sciences: Key Highlights
Table 36.4  Bioworkshops: Key Highlights
Table 36.5  Aldevron: Key Highlights
Table 36.6  Resilience: Key Highlights
Table 36.7  Minaris Regenerative Medicine: Key Highlights
Table 36.8  53Biologics: Key Highlights
Table 36.9  Richter-Helm BioLogics: Key Highlights
Table 37.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Table 37.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Table 37.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)
Table 37.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 37.5 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region)
Table 37.6 Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Table 37.7 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Table 37.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters (Region)
Table 37.9 Biopharmaceutical Contract Manufacturers: Distribution by Type of  Biologic Manufactured and Company Size
Table 37.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Table 37.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Table 37.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Table 37.13 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used and Location of Headquarters (Region)
Table 37.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Table 37.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Table 37.16 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Table 37.17 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered
Table 37.18 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Table 37.19 AGC Biologics: Annual Revenues, FY 2018-H1 FY 2023 (JPY Billion)
Table 37.20 Catalent: Annual Revenues, FY 2018-FY 2023 (USD Billion)
Table 37.21 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
Table 37.22 FUJIFILM Holdings: Annual Revenues by Business Divisions FY 2022 (JPY Billion)
Table 37.23 Charles River Laboratories: Annual Revenues, FY 2018- H1 FY 2023 (USD Billion)
Table 37.24 Boehringer Ingelheim: Annual Revenues, FY 2018- H1 FY 2023 (EUR Billion)
Table 37.25 Lonza: Annual Revenues, FY 2018-H1 FY 2023 (CHF Billion)
Table 37.26 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Table 37.27 Sandoz: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 37.28 Wuxi Biologics: Annual Revenues, FY 2018-H1 FY 2023 (RMB Billion)
Table 37.29 Samsung Biologics: Annual Revenues, FY 2018-H1 FY 2023 (KRW Billion)
Table 37.30 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Table 37.31 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indications
Table 37.32 Antibody Drug Conjugates: Distribution by Status of Development
Table 37.33 Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 37.34 Most Active Players: Distribution by Number of Therapies
Table 37.35 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Table 37.36 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Table 37.37 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Table 37.38 Stem Cell Therapies: Distribution by Phase of Development
Table 37.39 T-Cell Therapies: Distribution by Phase of Development
Table 37.40 Gene Therapies: Distribution by Stage of Development
Table 37.41 Gene Therapies: Distribution by Phase of Development
Table 37.42 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 37.43 Early-stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 37.44 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 37.45 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 37.46 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent)
Table 37.47 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 37.48 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 37.49 Biosimilars: Historical Trend of  FDA Approval, 2015-2022
Table 37.50 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022 
Table 37.51 Big Pharma Initiatives: Distribution of Players by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives
Table 37.52 Big Pharma Initiatives: Cumulative Year-wise Trend, Pre-2005-2023
Table 37.53 Big Pharma Initiatives: Distribution by Purpose of Initiative
Table 37.54 Big Pharma Initiatives: Distribution by Type of Initiative
Table 37.55 Big Pharma Initiatives: Distribution by Type of Partnership
Table 37.56 Big Pharma Initiatives: Distribution by Type of Expansion
Table 37.57 Big Pharma Initiatives: Distribution by Scale of Operation
Table 37.58 Big Pharma Initiatives: Distribution by Type of Biologic Manufactured
Table 37.59 Big Pharma Initiatives: Distribution of Players by Purpose of Initiative
Table 37.60 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Table 37.61 Big Pharma Initiatives: Distribution of Players by Region of Expansion 
Table 37.62 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Table 37.63 Partnerships and Collaborations: Distribution by Type of Partnership
Table 37.64 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 37.65 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Table 37.66 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Table 37.67 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured and Geography
Table 37.68 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured
Table 37.69 Partnerships and Collaborations: Distribution by Scale of Operation
Table 37.70 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 37.71 Most Active Players: Distribution by Number of Partnerships
Table 37.72 Partnerships and Collaborations: Local and International Agreements
Table 37.73 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 37.74 Mergers and Acquisitions: Year-Wise Cumulative Trend, 2015-2023
Table 37.75 Mergers and Acquisitions: Distribution by Type of Agreement
Table 37.76 Mergers and Acquisitions: Intracontinental and Intercontinental Agreements 
Table 37.77 Mergers and Acquisitions: Local and International Agreements
Table 37.78 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia- Pacific (2015-2023)
Table 37.79 Most Active Acquirers: Distribution by Number of Acquisitions
Table 37.80 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 37.81 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 37.82 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Table 37.83 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Table 37.84 Mergers and Acquisitions: Year-Wise Trend of Deal Multiple Amount (USD Million)
Table 37.85 Recent Expansions: Cumulative Year-wise Trend, 2016-2023
Table 37.86 Recent Expansions: Distribution by Purpose of Expansion
Table 37.87 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 37.88 Recent Expansions: Distribution by Type of Biologic Manufactured
Table 37.89 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Table 37.90 Recent Expansions: Distribution by Location of Expanded Facility
Table 37.91 Most Active Players: Distribution by Number of Recent Expansions
Table 37.92 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility
Table 37.93 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 37.94 Funding and Investment Analysis: Cumulative Year- wise Trend of Number of Funding Instances, 2016-2023
Table 37.95 Funding and Investment  Analysis: Cumulative Year- wise Trend of Total Amount Invested, 2016-2023 (USD Million)
Table 37.96 Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding
Table 37.97 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 37.98 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 37.99 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Continent) (USD Million)
Table 37.100 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Country) (USD Million)
Table 37.101 Most Active Players: Distribution by Number of Funding Instances
Table 37.102 Most Active Players: Distribution by Total Amount Raised (USD Million)
Table 37.103 Leading Investors: Distribution by Number of Funding Instances
Table 37.104 Leading Investors: Distribution by Total Amount Invested (USD Million)
Table 37.105 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Company Size
Table 37.106 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Type of Expression System Used
Table 37.107 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Location of Manufacturing Facilities
Table 37.108 Biopharmaceutical Contract Manufacturing Capacity in North America
Table 37.109 Biopharmaceutical Contract Manufacturing Capacity in Europe
Table 37.110 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Table 37.111 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
Table 37.112 Global Demand for Biopharmaceuticals, 2023-2235 (in kilograms)
Table 37.113 Global Demand for ADC Therapeutics, 2023-2035 (in kilograms)
Table 37.114 Global Demand for Cell Therapies, 2023-2035 (in terms of Number of Patients)
Table 37.115 Global Demand for Cell Therapies, 2023-2035 (Billion Cells)
Table 37.116 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 37.117 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 37.118 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 37.119 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 37.120 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 37.121 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 37.122 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.123 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, 2023 and 2035 (USD Billion)
Table 37.124 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.125 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.126 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, 2023 and 2035 (USD Billion)
Table 37.127 Biopharmaceutical Contract Manufacturing Market for Antibodies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.128 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.129 Biopharmaceutical Contract Manufacturing Market for Vaccines, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.130 Biopharmaceutical Contract Manufacturing Market for Other Biologics, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.131 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2023 and 2035 (USD Billion)
Table 37.132 Biopharmaceutical Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.133 Biopharmaceutical Contract Manufacturing Market for Microbial Expression Systems, Historical Trends (2018-2022) and Forecasted   Estimates (2023-2035) (USD Billion)
Table 37.134 Biopharmaceutical Contract Manufacturing Market for Other Expression Systems, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.135 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and 2035 (USD Billion)
Table 37.137 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.137 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.138 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035 (USD Billion)
Table 37.139 Biopharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.140 Biopharmaceutical Contract Manufacturing Market for Mid- sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.141 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.142 Biopharmaceutical Contract Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035 (USD Billion)
Table 37.143 Biopharmaceutical Contract Manufacturing Market in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.144 Biopharmaceutical Contract Manufacturing Market in the US, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.145 Biopharmaceutical Contract Manufacturing Market in Canada, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.146 Biopharmaceutical Contract Manufacturing Market in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.147 Biopharmaceutical Contract Manufacturing Market in Italy, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.148 Biopharmaceutical Contract Manufacturing Market in Germany, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.149 Biopharmaceutical Contract Manufacturing Market in France, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.150 Biopharmaceutical Contract Manufacturing Market in Spain, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.151 Biopharmaceutical Contract Manufacturing Market in the UK, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.152 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.153 Biopharmaceutical Contract Manufacturing Market in Asia- Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.154 Biopharmaceutical Contract Manufacturing Market in China, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.155 Biopharmaceutical Contract Manufacturing Market in India, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.156 Biopharmaceutical Contract Manufacturing Market in South Korea, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.157 Biopharmaceutical Contract Manufacturing Market in Japan, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.158 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.159 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.160 Biopharmaceutical Contract Manufacturing Market in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.161 Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players (USD Billion)
Table 31.162 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Contract Manufacturing Market in 2023 (USD Billion)
Table 37.163 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2005-2023
Table 39.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations, 2015 – 2018

List Of Companies

Please contact our sales team for the exhaustive list of companies. 

 

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com